Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone marrow transplantation Abdallah, N., Sidana, S., Dispenzieri, A., Lacy, M., Buadi, F., Hayman, S., Kapoor, P., Leung, N., Dingli, D., Hwa, Y. L., Lust, J., Russell, S., Gonsalves, W., Go, R., Hogan, W., Kyle, R., Rajkumar, S. V., Gertz, M., Kumar, S. 2020

Abstract

In the presence of effective treatment options for systemic light chain (AL) amyloidosis, autologous stem cell transplantation (ASCT) is sometimes deferred after stem cell collection. We designed this retrospective study to compare overall survival (OS) between patients who proceed directly to ASCT after stem cell collection and those who defer ASCT. We included patients with AL amyloidosis who had stem cell collection at Mayo Clinic, Minnesota, from 2004 to 2018. ASCT was considered "early" if performed within 90 days of collection, and "deferred" if performed after 90 days, or not done by last follow up. We included 651 patients; 527 underwent early ASCT and 124 deferred ASCT. There was no difference in OS with early vs. deferred ASCT (median OS: 13.0 vs. 11.4 years, respectively, P=0.28). There was no difference in OS between the 2 groups among patients with early or advanced Mayo Stage. Among patients who achieved =very good partial response at the time of collection, OS in the early and deferred groups was 14.2 and 13.4 years, respectively (P=0.06). Survival outcomes are similar with early and deferred ASCT. Further studies are needed to identify patients who would benefit from each approach.

View details for DOI 10.1038/s41409-020-0964-8

View details for PubMedID 32518290